InvestoGain

Investogain Pty Limited
AFS Licence No. 334036

All correspondence to:
admin@delisted.com.au
or by mail to:
PO Box 400
Crows Nest NSW 1585

26 April 2025

Name:

DIA-B TECH LIMITED (DIA)
(This company subsequently changed its name to PALLANE MEDICAL LIMITED. You should refer to that name for Status.)

Date of Listing:

24 January 2005

Subsequent Names:

Company Name	Start Date	End Date
PALLANE MEDICAL LIMITED	20/11/2009

Stock Exchange Status: (updated daily)

This company subsequently changed its name to PALLANE MEDICAL LIMITED. You should refer to that name for Stock Exchange Status.

Legal Status: (updated monthly)

This company subsequently changed its name to PALLANE MEDICAL LIMITED. You should refer to that name for Legal Status.

Capital Gains Tax (CGT) Status: (updated at least quarterly)

This company subsequently changed its name and is now PALLANE MEDICAL LIMITED. You should refer to that name for Capital Gains Tax Status.

Updates, corrections, disagreements please email to admin@delisted.com.au

Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.

Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.

Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.

DIA-B TECH LIMITED(DIA)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

	FROM	TO
DIA-B TECH LIMITED		20/11/2009

Shareholder links

REGISTRY:

No longer operating

Tel :
Fax :

Company details

Address: Suites 1133-1139 No 1 Queens Road Melbourne VIC 3004
Tel: +61 3 9863 9557 Fax: +61 3 9863 9556

Date first listed: 24/01/2005
Company Secretary:
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Discovery and development of pharmaceuticals, diagnostics and treatments for diabetes and diabetes-related diseases

News & Events

Expand this box to read and print

name changed to Pallane Medical Limited	20/11/2009
releases Annual Financial Report	30/10/2009
following the recent default of the Pallane Medical underwriting by Winteray Capital, that the Company has undertaken a review of all options available - following extensive negotiations, the convertible note holder in DIA, Trafalgar Capital Specialized Investment Fund, will take control of the Company through an agreement to convert the majority of the current convertible debt holdings into equity, subject to shareholder approval - the Board believes this is in the best interest of all creditors and shareholders - the Chairman, Dr Michael Wooldridge, non-executive Director Mr Neil Hewitt and CEO/Company Secretary Mr Ken Smith have stood aside and facilitated the appointment of the new Directors and management	05/10/2009
advises that it has received a notice of termination in relation to the share sale agreement for the acquisition of Pallane Medical Pty Ltd (Pallane). The Company's proposed acquisition of Pallane, as announced to the market on 12 February 2009, will no longer be completed on the terms of that agreement	13/08/2009
advises that Winteray Capital Pty Ltd, the underwriter under the Company's capital raising to fund the acquisition of Pallane Medical Pty Ltd (Offer), has not, to date, satisfied its obligation under the terms of the underwriting agreement to cause applications subscribing for the ordinary shares comprising the shortfall under the Offer to be lodged with the Company by Monday, 10 August 2009. The Company is seeking advice on this matter and will inform the market immediately of any further developments	11/08/2009
the Company advises that the offer period for its capital raising to fund the acquisition of Pallane Medical Pty Ltd closed Friday 31 July 2009 - there was a substantial shortfall in applications for shares in the Offer - the Offer is underwritten by Winteray Capital Pty Ltd (Underwriter) to the amount of $12.5 million - immediately following the close of the Offer, the Company served on the Underwriter a shortfall notice for the Underwriter to take up the Shortfall - in accordance with the terms of the underwriting agreement with the Underwriter, the Company expects applications to be lodged to subscribe for the ordinary shares comprising the Shortfall by no later than Monday, 10 August 2009	03/08/2009
company advises that it has extended the offer period for its capital raising to fund the acquisition of Pallane Medical Pty Ltd 2009 until Friday, 31 July 2009	28/07/2009
the process to consolidate the shares and options of the Company on a twenty (20) for one (1) basis is now complete in accordance with section 254H(1) of the Corporations Act. The consolidation was approved by shareholders at the Company's general meeting held on the 29 th June 2009	08/07/2009
the securities of Dia-B Tech Limited (the "Company") will be suspended from quotation immediately following security holder approval of the Company's acquisition of Pallane Medical Pty Limited and resultant change of activities	29/06/2009
securities reinstated to quotation	13/02/2009
the securities of Dia-B Tech Ltd (the "Company") will be suspended from quotation immediately, following the Company's announcement concerning the proposed acquisition of Pallane Medical Pty Ltd (the "Acquisition"). Unless ASX decides otherwise, the securities of the Company will be reinstated to official quotation prior to the commencement of trading on Friday, 13 February 2009	12/02/2009

name changed to Pallane Medical Limited	20/11/2009
releases Annual Financial Report	30/10/2009
following the recent default of the Pallane Medical underwriting by Winteray Capital, that the Company has undertaken a review of all options available - following extensive negotiations, the convertible note holder in DIA, Trafalgar Capital Specialized Investment Fund, will take control of the Company through an agreement to convert the majority of the current convertible debt holdings into equity, subject to shareholder approval - the Board believes this is in the best interest of all creditors and shareholders - the Chairman, Dr Michael Wooldridge, non-executive Director Mr Neil Hewitt and CEO/Company Secretary Mr Ken Smith have stood aside and facilitated the appointment of the new Directors and management	05/10/2009
advises that it has received a notice of termination in relation to the share sale agreement for the acquisition of Pallane Medical Pty Ltd (Pallane). The Company's proposed acquisition of Pallane, as announced to the market on 12 February 2009, will no longer be completed on the terms of that agreement	13/08/2009
advises that Winteray Capital Pty Ltd, the underwriter under the Company's capital raising to fund the acquisition of Pallane Medical Pty Ltd (Offer), has not, to date, satisfied its obligation under the terms of the underwriting agreement to cause applications subscribing for the ordinary shares comprising the shortfall under the Offer to be lodged with the Company by Monday, 10 August 2009. The Company is seeking advice on this matter and will inform the market immediately of any further developments	11/08/2009
the Company advises that the offer period for its capital raising to fund the acquisition of Pallane Medical Pty Ltd closed Friday 31 July 2009 - there was a substantial shortfall in applications for shares in the Offer - the Offer is underwritten by Winteray Capital Pty Ltd (Underwriter) to the amount of $12.5 million - immediately following the close of the Offer, the Company served on the Underwriter a shortfall notice for the Underwriter to take up the Shortfall - in accordance with the terms of the underwriting agreement with the Underwriter, the Company expects applications to be lodged to subscribe for the ordinary shares comprising the Shortfall by no later than Monday, 10 August 2009	03/08/2009
company advises that it has extended the offer period for its capital raising to fund the acquisition of Pallane Medical Pty Ltd 2009 until Friday, 31 July 2009	28/07/2009
the process to consolidate the shares and options of the Company on a twenty (20) for one (1) basis is now complete in accordance with section 254H(1) of the Corporations Act. The consolidation was approved by shareholders at the Company's general meeting held on the 29 th June 2009	08/07/2009
the securities of Dia-B Tech Limited (the "Company") will be suspended from quotation immediately following security holder approval of the Company's acquisition of Pallane Medical Pty Limited and resultant change of activities	29/06/2009
securities reinstated to quotation	13/02/2009
the securities of Dia-B Tech Ltd (the "Company") will be suspended from quotation immediately, following the Company's announcement concerning the proposed acquisition of Pallane Medical Pty Ltd (the "Acquisition"). Unless ASX decides otherwise, the securities of the Company will be reinstated to official quotation prior to the commencement of trading on Friday, 13 February 2009	12/02/2009

Your browser may reflect a date of printing in American format.

ASX Announcements (courtesy of ASX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

Company Updates

Post your comments here

Please read our Terms before posting comments.

Click here for free access to this company's:
ASX, Legal & CGT Status

Directors' on-market share transactions (last 5)

Click here for the last 20 transactions all companies

Directors & Executives (current)

NAME	TITLE	DATE OF APPT
Ravindran Govindan	Chairman	05/10/2009
Peter Stafford	Director	05/10/2009
Joanna Broeders	Director	05/10/2009
Sam Di-Giacomo	Director, Company Secretary	05/10/2009

Date of first appointment, title may have changed.

Directors & Executives (former)

NAME	TITLE	DATE OF APPOINTMENT	DATE OF RESIGNATION

Date of first appointment, title may have changed.